Werewolf Therapeutics, INC Form 4 insider transactions

Steven H. Bloom, Chief Business Officer of Werewolf Therapeutics, Inc., reports the acquisition of stock options.

MPM BioVentures 2014, L.P. exercised warrants to purchase shares of Werewolf Therapeutics, Inc. common stock and subsequently disposed of a portion of those shares to cover the exercise price.

Director Luke Evnin reports exercising warrants and selling shares of Werewolf Therapeutics, Inc.

Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, exercised warrants to purchase shares and subsequently sold a portion of those shares.

Anil K. Singhal, a director of Werewolf Therapeutics, Inc., was granted stock options to purchase 45,000 shares of common stock on February 19, 2025.

Ellen Lubman, Chief Business Officer of Werewolf Therapeutics, Inc., was granted stock options to purchase 131,900 shares of common stock on January 2, 2025.

Chief Financial Officer of Werewolf Therapeutics, Timothy W. Trost, reports acquisition of stock options.

Randi Isaacs, Chief Medical Officer of Werewolf Therapeutics, reports the acquisition of stock options on January 2, 2025.

Chulani Karunatilake, Chief Technology Officer of Werewolf Therapeutics, received stock options on January 2, 2025.

Werewolf Therapeutics CEO, Daniel J. Hicklin, was granted stock options on January 2, 2025, according to a recent SEC filing.

RA Capital Management, along with related entities and individuals, reports the acquisition of stock options in Werewolf Therapeutics.

Director Derek DiRocco of Werewolf Therapeutics, Inc. was granted stock options but disclaims beneficial ownership due to an arrangement with RA Capital Management, L.P.

Director Briggs Morrison of Werewolf Therapeutics acquired stock options on May 24, 2024, according to a recent SEC Form 4 filing.

Director Michael B. Atkins of Werewolf Therapeutics, Inc. reports acquisition of stock options on May 24, 2024.

Meeta Chatterjee, a director of Werewolf Therapeutics, Inc., was granted stock options to purchase 17,500 shares of common stock at an exercise price of $4.88 on May 24, 2024.

Director Michael A. Sherman acquired 17,500 stock options in Werewolf Therapeutics, Inc. on May 24, 2024.

Director Luke Evnin acquired 17,500 stock options in Werewolf Therapeutics, Inc. on May 24, 2024.

Director Alon Lazarus acquired 17,500 stock options in Werewolf Therapeutics on May 24, 2024, at an exercise price of $4.88.